PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/WMV865. CME/NCPD/AAPA credit will be available until March 25, 2025. Conversations With Peers About T2DM: Best Practices for Optimizing Treatment Using Weight Management as a Primary Goal In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Lilly. Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/GVK865. CME credit will be available until February 13, 2025. Targeting Elevated Cardiovascular Risk: Current Therapies and New Horizons in Hyperlipidemia Management The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education. Support This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation. Disclosures R. Scott Wright, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Novo Nordisk Inc. CME Reviewer Ramil Goel Assistant Professor of Medicine Division of Cardiovascular Medicine Electrophysiology Section University of Florida College of Medicine Gainesville, Florida Ramil Goel, MD, FHRS, has no relevant financial relationships to disclose.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ANR865. CME/MOC/CC/NCPD/CPE/AAPA/IPCE credit will be available until January 16, 2025. Adapting Our Strategies for Decision-Making in Testing and Treatment of RET-Altered Lung and Thyroid Cancers: A Personalized Learning Journey In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Lilly. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Co-Chair/Planner Professor Benjamin Solomon, MBBS, PhD, FRACP, FAHMS, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Bristol Myers Squibb; D3 BIO, INC; F. Hoffmann-La Roche AG; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharpe & Dohme; Pfizer; and Takeda Pharmaceutical Company. Speakers Bureau participant with AstraZeneca; F. Hoffmann-La Roche AG; and Pfizer. Co-Chair/Planner Lori J. Wirth, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc.; Blueprint Medicines Corporation; Coherus BioSciences; Eisai Co., Ltd.; Ellipses Pharma Ltd; EMD Serono, Inc.; Exelixis, Inc.; Lilly; Merck & Co., Inc.; and Nested Therapeutics. Data Safety Monitoring Board for PDS Biotechnology. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/CPD information, and to apply for credit, please visit us at PeerView.com/BVW865. CME/CPD credit will be available until December 27, 2024. Tools of the Trade: Prioritising Weight Management in People With Type 2 Diabetes – Sharpening Your Skills to Intensify Therapy and Engage in Shared Decision-Making In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Lilly. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Chair/Planner Stefano Del Prato, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Abbott; Amarin Corporation plc; Applied Therapeutics; EvaPharma; Lilly; The Menarini Group; Novo Nordisk A/S; Sanofi; and Sun Pharmaceutical Industries Ltd. Speaker for Abbott; AstraZeneca; Berlin-Chemie AG; Boehringer Ingelheim International GmbH; Laboratori Guidotti S.p.a.; Lilly; The Menarini Group; Merck Sharp & Dohme; and Novo Nordisk A/S. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/XCX865. CME/AAPA credit will be available until November 26, 2024. Cases in the Community: Optimizing Treatment and Considering Weight Management as a Primary Goal in People With T2DM In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Lilly. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Co-Chair/Planner Javier Morales, MD, FACP, FACE, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly; and Novo Nordisk Inc. Speaker for Amgen Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly; and Novo Nordisk Inc. Co-Chair/Planner Jay H. Shubrook, DO, FAAFP, FACOFP, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Abbott; AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Lilly; Nevro Corp.; and Novo Nordisk Inc. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/ZSZ865. CME credit will be available until November 4, 2024. Chronic Kidney Disease in Patients With Type 2 Diabetes: The Impetus for Early Recognition and Strategies for Coordinating Optimal, Patient-Centered Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Co-Chair/Planner Hiddo J.L. Heerspink, PhD, PharmD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Chinook Therapeutics Inc.; CSL Behring; Dimerix; Gilead Sciences, Inc.; Janssen-Cilag B.V.; Lilly; Merck & Co., Inc.; Novartis AG; Novo Nordisk A/S; and Travere Therapeutics, Inc. Grant/Research Support from AstraZeneca; Janssen-Cilag B.V.; and Novo Nordisk A/S. Speaker for AstraZeneca; Lilly; and Novo Nordisk A/S. Co-Chair/Planner Prof. Dr. med Christoph Wanner has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; GSK; and Merck Sharp & Dohme. Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc. Speaker for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; and GSK. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/NYY865. CME credit will be available until August 30, 2024. Can YOU Avoid Iatrogenic Harm? Understanding and Identifying Fibrodysplasia Ossificans Progressiva In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and International Fibrodysplasia Ossificans Progressiva Association ,Progressive Osseous & Heteroplasia Association ,The American Society for Bone and Mineral Research. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Co-Chair/Planner Richard Keen, PhD, FRCP, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Ipsen Biopharmaceuticals, Inc.; Kyowa Kirin Co., Ltd; Regeneron Pharmaceuticals Inc.; and UCB, Inc. Grant/Research Support from Incyte; Ipsen Biopharmaceuticals, Inc.; Kyowa Kirin Co., Ltd; and Regeneron Pharmaceuticals Inc. Speaker for Ipsen Biopharmaceuticals, Inc.; Kyowa Kirin Co., Ltd; Regeneron Pharmaceuticals Inc.; and UCB, Inc. Co-Chair/Planner Edna E. Mancilla, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Ipsen Biopharmaceuticals, Inc./Clementia Pharmaceuticals. Grant/Research Support from Incyte. Patient/Planner Erin Danzer has no financial interests/relationships or affiliations in relation to this activity. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Go online to PeerView.com/XZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the United States, the prevalence of obesity has been steadily increasing. Despite the number of obesity specialists in the United States multiplying five-fold from 2011 to 2019, there is an inadequate number of trained professionals to treat all people requiring obesity-targeted care. Primary care is often the first and only touch point for many people with obesity (PwO), and there is a need to equip and prepare primary care professionals (PCPs) to treat this patient population with empathetic, effective, and evidence-based obesity-targeted care. This PeerView Train-the-Trainer MasterClass activity combines concise overviews of essential evidence with training resources to help you, as an obesity specialist, lead the charge to educate your PCP colleagues. Using practical exercises, experts provide guidance on strategies and tactics you can use to create your own training workshop for PCPs. In addition to the Train-the-Trainer video, participants also have free access to a slide library, surveys, and practice aids to create their own independent training workshop. Upon completion of this activity, participants should be better able to: Address misperceptions and weight biases held by many PCPs to minimize the downstream effects and complications in people with obesity; and Assist PCPs in combating clinical inertia and encouraging early intervention in people with or at risk for obesity

Go online to PeerView.com/PQU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Type 2 diabetes (T2D) is a progressive disease that is largely preventable and entirely treatable. Timely intensification of therapy is a foundational principle of contemporary management of people with T2D since this strategy is associated with better long-term health outcomes. In conjunction with intensified therapy, modest weight loss has been shown to improve overall and long-term health outcomes. In this activity, based on a series of Project ECHO® workshops and produced in collaboration with the American College of Diabetology, you’ll learn best practices for individualizing patient care and intensifying therapy with evidence-based pharmacologic management of T2D with non-insulin glucose-lowering therapies. Now is the time! Watch today to begin adding these practical strategies to your toolbox! Upon completion of this activity, participants should be better able to: Intensify treatment in people with T2D consistent with the latest guidelines, available evidence, and shared decision-making principles to control glycemia and weight to optimize outcomes and avoid long-term complications; Explain the rationale for targeting weight and establish personalized weight loss goals as a treatment priority for comprehensive T2D management; and Counsel people with T2D about the relationship between obesity and diabetes and the importance of achieving and maintaining a healthy weight as a T2D treatment priority.

Go online to PeerView.com/ZAB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The availability of recombinant human growth hormone (rhGH) therapy has facilitated wider treatment of growth hormone deficiency. In this CME-certified MasterClass & Practicum video activity, expert faculty will review current guidelines for pediatric growth hormone deficiency diagnosis, growth hormone therapy indications, and characteristics of available and emerging growth hormone therapies. Tune in today to increase your knowledge and competence on the diagnosis and management of growth hormone deficiency with rhGH therapy, including long-acting growth hormone agents, and gain a better understanding of how to address patient needs. Upon completion of this activity, participants should be better able to: Utilize relevant diagnostic tests to provide timely diagnosis of pediatric patients suspected to have growth hormone deficiency; Compare the clinical characteristics and supporting evidence (eg, efficacy, safety and tolerability, ease of administration, dosing frequency) for various options in growth hormone therapy; and Incorporate growth hormone therapy into personalized management plans to address pediatric patient challenges such as dosage concerns, administration, adherence, and monitoring.

Go online to PeerView.com/WEU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. People with type 2 diabetes mellitus (T2DM) deserve care that is timely and of the appropriate intensity to reduce risks and improve long-term outcomes. To that end, GLP-1 receptor agonists (RAs) must be considered in a new light. Their role has escalated in recent years, including their positioning in treatment, due to their multifaceted mechanisms of action and the collective body of evidence validating their glycemic and extra-glycemic effects. In fact, these agents have consistently demonstrated high glycemic efficacy while reducing cardiovascular and renal risks with a favorable impact on weight and a low risk of hypoglycemia in patients with T2DM. Watch this expert-led activity to learn about GLP-1 RA options and get practical advice for integrating them into personalized care. Upon completion of this activity, participants should be better able to: Differentiate GLP-1 RAs and other glucose-lowering agents with regard to their current placement in treatment guidelines, glycemic and extra-glycemic effects, safety, ease of administration, and dosing frequency; Identify people with T2DM who would benefit from the glycemic and extra-glycemic effects of GLP-1 RAs to reduce cardiometabolic and renal risks, improve long-term health outcomes, and increase treatment adherence; and Incorporate GLP-1 RAs into personalized treatment regimens early to reduce cardiometabolic and renal risks in people with T2DM

Go online to PeerView.com/KNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Insulin is indispensable to the treatment of diabetes, but its use in people with diabetes presents numerous well-known challenges. As many as 40% of people with T2DM require insulin therapy, but only about one-third initiate basal insulin. How can endocrinologists and other healthcare providers ease the treatment burden for these patients? Part of the answer may lie in once-weekly basal insulins. This PeerView inQuiry challenges you to examine the role of once-weekly basal insulins and how they may help to improve outcomes in patients with diabetes. Four assessment questions will keep you on your toes, and an expert will share short, authoritative explanations on the latest clinical data, rationale for use, dosing and tips and strategies for helping patients achieve glycemic targets with less frequent basal insulin injection. Upon completion of this activity, participants should be better able to: Compare the efficacy, safety, administration, and dosing frequency of once-weekly with once-daily basal insulins; and Identify patients with T2DM that are not meeting individualized glycemic goals and who may benefit from basal insulin therapy, including once-weekly formulations, as they become available

Go online to PeerView.com/KNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Insulin is indispensable to the treatment of diabetes, but its use in people with diabetes presents numerous well-known challenges. As many as 40% of people with T2DM require insulin therapy, but only about one-third initiate basal insulin. How can endocrinologists and other healthcare providers ease the treatment burden for these patients? Part of the answer may lie in once-weekly basal insulins. This PeerView inQuiry challenges you to examine the role of once-weekly basal insulins and how they may help to improve outcomes in patients with diabetes. Four assessment questions will keep you on your toes, and an expert will share short, authoritative explanations on the latest clinical data, rationale for use, dosing and tips and strategies for helping patients achieve glycemic targets with less frequent basal insulin injection. Upon completion of this activity, participants should be better able to: Compare the efficacy, safety, administration, and dosing frequency of once-weekly with once-daily basal insulins; and Identify patients with T2DM that are not meeting individualized glycemic goals and who may benefit from basal insulin therapy, including once-weekly formulations, as they become available

Go online to PeerView.com/KNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Insulin is indispensable to the treatment of diabetes, but its use in people with diabetes presents numerous well-known challenges. As many as 40% of people with T2DM require insulin therapy, but only about one-third initiate basal insulin. How can endocrinologists and other healthcare providers ease the treatment burden for these patients? Part of the answer may lie in once-weekly basal insulins. This PeerView inQuiry challenges you to examine the role of once-weekly basal insulins and how they may help to improve outcomes in patients with diabetes. Four assessment questions will keep you on your toes, and an expert will share short, authoritative explanations on the latest clinical data, rationale for use, dosing and tips and strategies for helping patients achieve glycemic targets with less frequent basal insulin injection. Upon completion of this activity, participants should be better able to: Compare the efficacy, safety, administration, and dosing frequency of once-weekly with once-daily basal insulins; and Identify patients with T2DM that are not meeting individualized glycemic goals and who may benefit from basal insulin therapy, including once-weekly formulations, as they become available

Go online to PeerView.com/KNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Insulin is indispensable to the treatment of diabetes, but its use in people with diabetes presents numerous well-known challenges. As many as 40% of people with T2DM require insulin therapy, but only about one-third initiate basal insulin. How can endocrinologists and other healthcare providers ease the treatment burden for these patients? Part of the answer may lie in once-weekly basal insulins. This PeerView inQuiry challenges you to examine the role of once-weekly basal insulins and how they may help to improve outcomes in patients with diabetes. Four assessment questions will keep you on your toes, and an expert will share short, authoritative explanations on the latest clinical data, rationale for use, dosing and tips and strategies for helping patients achieve glycemic targets with less frequent basal insulin injection. Upon completion of this activity, participants should be better able to: Compare the efficacy, safety, administration, and dosing frequency of once-weekly with once-daily basal insulins; and Identify patients with T2DM that are not meeting individualized glycemic goals and who may benefit from basal insulin therapy, including once-weekly formulations, as they become available

Go online to PeerView.com/ZKJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Type 2 diabetes mellitus (T2DM) is a worldwide health concern. With more people living longer, the prevalence of chronic comorbid diseases has increased dramatically, and there is a resurgence in diabetic complications. T2DM shares risk factors with atherosclerotic cardiovascular disease (ASCVD), the leading cause of death among patients with T2DM. Furthermore, T2DM is a leading cause of kidney failure. How can clinicians address the underlying pathophysiology and comorbid organ damage that is frequently associated with T2DM? This activity seeks to answer that question using patient cases to examine where GLP-1 receptor agonists (RAs) fit in modern treatment algorithms and help recognize the differences between GLP-1 RA options. Importantly, you’ll also hear practical strategies to help navigate the ins and outs of patient-centered care. Upon completion of this activity, participants should be better able to: Explain the rationale for using GLP-1 RAs in comprehensive T2DM management plans to optimize patient outcomes and reduce the risk of associated complications; Compare current and emerging agents targeting GLP-1 based on their mechanisms of action, dosing frequency, efficacy, safety, and tolerability profiles; Identify patients who would benefit from the multifaceted glycemic and extra-glycemic effects of GLP-1 RAs as part of comprehensive T2DM management plans; and Counsel, as a member of a multidisciplinary care team, patients with T2DM about the long-term efficacy, safety, and convenience that GLP-1 RAs have to offer as a means to achieving individualized glycemic and non-glycemic health goals

Go online to PeerView.com/KEW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Early intervention is central to reducing excess weight gain and the risk of obesity-related comorbidities, yet many people never receive a formal diagnosis or specialty obesity care. With this in mind, how can clinicians best support this patient population? Endocrinologists, in particular, are on the front lines of managing and treating this complex disease. In this PeerView inReview, an expert uses patient videos to explain what you need to know about effective, compassionate patient communication and offers practical guidance on how to best integrate anti-obesity medications into patient care to improve long-term outcomes. Upon completion of this activity, participants should be better able to: Prioritize obesity as a chronic, progressive disease that requires individualized, long-term management; Initiate nonjudgmental conversations with individuals living with obesity and engage in effective shared decision-making discussions to achieve sustained weight loss; Compare the mechanism of action, efficacy, and safety of approved and emerging medications for the long-term management of obesity; and Identify people with obesity who could benefit from treatment with anti-obesity medications

Go online to PeerView.com/KNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Insulin is indispensable to the treatment of diabetes, but its use in people with diabetes presents numerous well-known challenges. As many as 40% of people with T2DM require insulin therapy, but only about one-third initiate basal insulin. How can endocrinologists and other healthcare providers ease the treatment burden for these patients? Part of the answer may lie in once-weekly basal insulins. This PeerView inQuiry challenges you to examine the role of once-weekly basal insulins and how they may help to improve outcomes in patients with diabetes. Four assessment questions will keep you on your toes, and an expert will share short, authoritative explanations on the latest clinical data, rationale for use, dosing and tips and strategies for helping patients achieve glycemic targets with less frequent basal insulin injection. Upon completion of this activity, participants should be better able to: Compare the efficacy, safety, administration, and dosing frequency of once-weekly with once-daily basal insulins; and Identify patients with T2DM that are not meeting individualized glycemic goals and who may benefit from basal insulin therapy, including once-weekly formulations, as they become available.

Go online to PeerView.com/QFA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this engaging activity, which is based on a pre-conference workshop held at OMA 2023, experts in obesity management aim to change misperceptions about obesity and explain best practices for treating this chronic condition, which include the importance of anti-obesity medications (AOMs) in achieving individualized weight goals and improving overall health outcomes by reducing the risk and progression of obesity-related comorbidities. Upon completion of this activity, participants should be better able to: Initiate appropriate, unbiased, and nonjudgmental conversations with patients about obesity acknowledging it as a chronic, treatable disease rather than a result of personal irresponsibility; Compare the efficacy and safety profiles of current and emerging anti-obesity medications and their potential to support weight loss efforts and minimize the impact of obesity-related comorbidities; and Employ shared decision-making to implement a comprehensive, individualized treatment plan that incorporates appropriate use of long-term anti-obesity medications to achieve and maintain realistic weight loss in people with obesity.

Go online to PeerView.com/JKX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. An expert in hypersomnolence discusses the diagnosis, classification, and treatment of narcolepsy and idiopathic hypersomnia. Using real-life cases as examples, the latest data and guidelines are reviewed in juxtaposition with the patients’ stories. Upon completion of this activity, participants should be better able to: Describe how delayed diagnosis of narcolepsy or idiopathic hypersomnia (IH) exacerbates the multifaceted burdens associated with both conditions; Apply International Classification of Sleep Disorders criteria to assess patients who present with excessive daytime sleepiness (EDS) or other signs or symptoms suggesting narcolepsy or IH; and Individualize treatment of narcolepsy and IH, based on the latest clinical evidence and guidelines; patient needs, preferences, and comorbidities; and considerations that affect adherence.